Integrin α4β7 expression on lymphocytes promotes their localization to the gut. A monoclonal antibody against these integrins (i.e. vedolizumab) is safe and effective treatment for inflammatory bowel disease (IBD). Given the importance of integrins on IBD pathogenesis, we evaluated the role of integrin β7 (Itgb7) in a model of Crohn’s-like ileitis, the TNFΔARE mouse.